FDA
-
-
-
-
-
-
-
Barclays Downgrades Gossamer Bio Inc. (GOSS) to Underweight
-
-
-
-
-
-
-
Gossamer Bio signs option deal to acquire Respira Therapeutics
-
-
-
-
-
-
-
Gossamer Bio Announces First Quarter 2023 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Gossamer Bio to Host Webcast Focused on GB002 and Pulmonary Arterial Hypertension (PAH) on December 15, 2020
-
-
-
-
-
-
-
Gossamer Bio Announces First Quarter 2020 Financial Results and Provides Corporate Update
-
-
-
-
325,025 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

